127 related articles for article (PubMed ID: 15233210)
1. The quality of life in acromegaly.
Pantanetti P; Sonino N; Arnaldi G; Boscaro M
J Endocrinol Invest; 2003; 26(8 Suppl):35-8. PubMed ID: 15233210
[No Abstract] [Full Text] [Related]
2. The effects of somatostatin analogs on biochemical parameters in acromegaly.
Liuzzi A; Marzullo P
J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212
[No Abstract] [Full Text] [Related]
3. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
[No Abstract] [Full Text] [Related]
4. [Complete regression of a somatotropin-secreting adenoma with lanreotide monotherapy].
Ilias I; Mastorakos G
Presse Med; 2000 Nov; 29(33):1818-9. PubMed ID: 11109436
[No Abstract] [Full Text] [Related]
5. The effects of somatostatin analogs on tumor shrinkage in acromegaly.
Pedroncelli AM; Montini M; Albizzi M; Barbò R; Pagani G
J Endocrinol Invest; 2003; 26(8 Suppl):50-4. PubMed ID: 15233213
[No Abstract] [Full Text] [Related]
6. The treatment algorithm of acromegaly.
Colao A; Pivonello R; Cappabianca P; Vitale G; Lombardi G
J Endocrinol Invest; 2003; 26(8 Suppl):39-45. PubMed ID: 15233211
[No Abstract] [Full Text] [Related]
7. Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate.
Teltayev D; Akshulakov S; Ryskeldiev N; Mustafin K; Vyacheslav L
Gynecol Endocrinol; 2017; 33(sup1):50-51. PubMed ID: 29264984
[TBL] [Abstract][Full Text] [Related]
8. Rationale of pre-surgical medical treatment with somatostatin analogs in acromegaly.
Cappabianca P; Cavallo LM; Esposito F; Romano I; Colao A; de Divitiis E
J Endocrinol Invest; 2003; 26(8 Suppl):55-8. PubMed ID: 15233214
[No Abstract] [Full Text] [Related]
9. Somatostatin analogs in acromegaly.
Freda PU
J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
[No Abstract] [Full Text] [Related]
10. [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
Wasko R; Sawicka J; Stachowiak C; Kozak W; Junik R; Sowinski J
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):532-5. PubMed ID: 12527855
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
12. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
13. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
14. Long-term primary medical therapy with somatostatin analogs in acromegaly.
Su DH; Liao KM; Chen HW; Chang TC
J Formos Med Assoc; 2006 Aug; 105(8):664-9. PubMed ID: 16935768
[TBL] [Abstract][Full Text] [Related]
15. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly.
Ben-Shlomo A; Melmed S
J Clin Endocrinol Metab; 2003 Mar; 88(3):963-8. PubMed ID: 12629068
[No Abstract] [Full Text] [Related]
16. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
17. [Acromegalic myocardiopathy].
Clemente Gallego D; Gómez Bueno M; Lucas Morante T
Endocrinol Nutr; 2009 Feb; 56(2):96-8. PubMed ID: 19627718
[TBL] [Abstract][Full Text] [Related]
18. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
Colao A; Pivonello R; Auriemma RS; Briganti F; Galdiero M; Tortora F; Caranci F; Cirillo S; Lombardi G
J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and limits of somatostatin analogs.
Petersenn S
J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
[TBL] [Abstract][Full Text] [Related]
20. Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?
Chanson P
Eur J Endocrinol; 1997 Apr; 136(4):359-61. PubMed ID: 9150692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
